Immusoft’s ISP-002 designated US orphan drug for MPS II
Endocrine/metabolic Immusoft of CA Inc., a wholly owned subsidiary of Immusoft Corp., has announced that the FDA has granted orphan drug designation to ISP-002, the company’s investigational engineered B-cell therapy for the treatment of …